|
1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Suppliers list
|
1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- manufacturers
- BI-4020
-
- $173.00
-
2026-07-27
- CAS:2664214-60-0
- Purity: 99.74%
- Supply Ability: 10g
- BI-4020
-
- $173.00
-
2026-07-27
- CAS:2664214-60-0
- Purity: 99.74%
- Supply Ability: 10g
|
| | 1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Basic information |
| Product Name: | 1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- | | Synonyms: | HER1,BI-4020,inhibit,BI4020,BI 4020,Epidermal growth factor receptor,ErbB-1,Inhibitor,EGFR;BI-4020, 10 mM in DMSO;1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- | | CAS: | 2664214-60-0 | | MF: | C30H38N8O2 | | MW: | 542.68 | | EINECS: | | | Product Categories: | | | Mol File: | 2664214-60-0.mol | ![1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Structure](CAS/20211123/GIF/2664214-60-0.gif) |
| | 1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Chemical Properties |
| Boiling point | 736.6±70.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | pka | 7.60±0.10(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | 1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Usage And Synthesis |
| Uses | BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties[1]. | | in vivo | BI-4020 leads to tumor regressions in the human PC-9 (EGFR del19 T790M C797S) triple mutant NSCLC xenograft model in mice[1]. | | IC 50 | EGFRdel19 T790M C797S: 0.2 nM (IC50); EGFRdel19: 1 nM (IC50); EGFRWT: 190 nM (IC50); EGFRdel19 T790M | | References | [1] Engelhardt H,et al. Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors. J Med Chem. 2019 Nov 5. DOI:10.1021/acs.jmedchem.9b01169 |
| | 1H-4,8-Metheno-17H-pyrazolo[3′,4′:2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-9(11H)-one, 18,19,20,21-tetrahydro-1,6,18-trimethyl-14-[(4-methyl-1-piperazinyl)methyl]-, (10E,18R)- Preparation Products And Raw materials |
|